EXACT SCIENCES CORP Quarterly Debt-to-equity in % from Q3 2015 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Exact Sciences Corp quarterly Debt-to-equity history and growth rate from Q3 2015 to Q3 2024.
  • Exact Sciences Corp Debt-to-equity for the quarter ending September 30, 2024 was 107 %, a 0.99% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 107 +1.05 +0.99% Sep 30, 2024
Q2 2024 106 +0.64 +0.61% Jun 30, 2024
Q1 2024 106 +2.2 +2.13% Mar 31, 2024
Q4 2023 106 +4.62 +4.54% Dec 31, 2023
Q3 2023 106 +6.18 +6.18% Sep 30, 2023
Q2 2023 105 +8.08 +8.3% Jun 30, 2023
Q1 2023 104 +9.16 +9.71% Mar 31, 2023
Q4 2022 102 +11.1 +12.2% Dec 31, 2022
Q3 2022 99.9 +5.86 +6.23% Sep 30, 2022
Q2 2022 97.3 -0.75 -0.77% Jun 30, 2022
Q1 2022 94.4 -8.23 -8.02% Mar 31, 2022
Q4 2021 90.7 -20.1 -18.2% Dec 31, 2021
Q3 2021 94.1 -1.15 -1.21% Sep 30, 2021
Q2 2021 98.1 +3.92 +4.16% Jun 30, 2021
Q1 2021 103 +6.29 +6.53% Mar 31, 2021
Q4 2020 111 +11 +11.1% Dec 31, 2020
Q3 2020 95.2 -45.9 -32.5% Sep 30, 2020
Q2 2020 94.1 -40.6 -30.1% Jun 30, 2020
Q1 2020 96.3 -29.1 -23.2% Mar 31, 2020
Q4 2019 99.8 -13.7 -12% Dec 31, 2019
Q3 2019 141 +59.5 +72.8% Sep 30, 2019
Q2 2019 135 +76.4 +131% Jun 30, 2019
Q1 2019 125 +92.5 +280% Mar 31, 2019
Q4 2018 113 +102 +875% Dec 31, 2018
Q3 2018 81.7 +70.9 +658% Sep 30, 2018
Q2 2018 58.3 +47.7 +446% Jun 30, 2018
Q1 2018 33 +20 +155% Mar 31, 2018
Q4 2017 11.6 -1.09 -8.56% Dec 31, 2017
Q3 2017 10.8 -1.67 -13.4% Sep 30, 2017
Q2 2017 10.7 -1.11 -9.42% Jun 30, 2017
Q1 2017 12.9 +1.82 +16.4% Mar 31, 2017
Q4 2016 12.7 +2.6 +25.7% Dec 31, 2016
Q3 2016 12.4 +3.15 +33.9% Sep 30, 2016
Q2 2016 11.8 Jun 30, 2016
Q1 2016 11.1 Mar 31, 2016
Q4 2015 10.1 Dec 31, 2015
Q3 2015 9.29 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.